Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.51 |
| ▸ | USP2 | O75604 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17276315 | 0.98 | CYP2D6 (0.51) | CYP2D6USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17276506 | 0.97 | CYP2D6 (0.50) | CYP2D6USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17276497 | 0.91 | CYP2D6 (0.48) | CYP2D6USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL19078748 | 0.82 | TSHR (0.50) | CYP2D6USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL17276477 | 0.79 | LSS (0.54) | CYP2D6CYP3A4CYP2C9SMN1; SMN2ALDH1A1 | |
| SCHEMBL17276478 | 0.79 | ALDH1A1 (0.62) | TSHRALDH1A1MEN1MAPK1KMT2A | |
| SCHEMBL17276428 | 0.79 | CYP3A4 (0.48) | CYP2D6USP2CYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL17276280 | 0.78 | KDM4E (0.45) | TSHRSMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL17276277 | 0.78 | CHKA (0.44) | — | |
| SCHEMBL17276378 | 0.77 | LSS (0.54) | CYP2D6CYP3A4CYP2C9SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABIDE THERAPEUTICS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2017-07-06 | — | — | US | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015179559-A2 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190669-A1 | PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, FAAH, FAAH2 | CYP2D6 64/4885USP2 548/4885CYP3A4 976/4885 |
| US-10093630-B2 | Pyrazole compounds and methods of making and using same | ABHD6, FAAH, FAAH2 | CYP2D6 64/4885USP2 548/4885CYP3A4 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.